Total Payments
$44,958
2024 Payments
$3,797
Companies
6
Transactions
69
Medicare Patients
481
Medicare Billing
$62,450
Payment Breakdown by Category
Other$39,648 (88.2%)
Consulting$3,115 (6.9%)
Travel$1,756 (3.9%)
Food & Beverage$439.68 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $39,648 | 55 | 88.2% |
| Consulting Fee | $3,115 | 3 | 6.9% |
| Travel and Lodging | $1,756 | 4 | 3.9% |
| Food and Beverage | $439.68 | 7 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BeiGene USA, Inc. | $14,978 | 21 | $0 (2023) |
| Janssen Biotech, Inc. | $11,561 | 17 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $8,862 | 11 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $8,470 | 17 | $0 (2024) |
| Incyte Corporation | $1,050 | 1 | $0 (2024) |
| Gilead Sciences, Inc. | $36.89 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,797 | 9 | AstraZeneca Pharmaceuticals LP ($2,372) |
| 2023 | $8,656 | 14 | AstraZeneca Pharmaceuticals LP ($2,983) |
| 2022 | $10,315 | 15 | Janssen Biotech, Inc. ($3,825) |
| 2021 | $22,190 | 31 | BeiGene USA, Inc. ($10,938) |
All Payment Transactions
69 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/06/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 07/12/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,150.00 | General |
| Category: Oncology | ||||||
| 07/10/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $106.75 | General |
| Category: Oncology | ||||||
| 07/10/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $15.41 | General |
| Category: Oncology | ||||||
| 06/18/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $100.00 | General |
| Category: Oncology | ||||||
| 05/22/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Oncology | ||||||
| 04/01/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Oncology | ||||||
| 02/18/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $100.00 | General |
| Category: Oncology | ||||||
| 01/17/2024 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $375.00 | General |
| Category: Oncology | ||||||
| 12/12/2023 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: COVID-19 | ||||||
| 11/19/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Travel and Lodging | In-kind items and services | $745.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $117.00 | General |
| Category: ONCOLOGY | ||||||
| 10/12/2023 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: COVID-19 | ||||||
| 08/30/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,750.00 | General |
| Category: Oncology | ||||||
| 08/23/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $558.39 | General |
| Category: Oncology | ||||||
| 08/23/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $74.50 | General |
| Category: Oncology | ||||||
| 06/30/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Oncology | ||||||
| 06/20/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Travel and Lodging | In-kind items and services | $437.18 | General |
| Category: Oncology | ||||||
| 06/20/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $86.68 | General |
| Category: Oncology | ||||||
| 05/26/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| Category: Oncology | ||||||
| 05/01/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Oncology | ||||||
| 05/01/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Oncology | ||||||
| 10/01/2022 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Oncology | ||||||
| 07/22/2022 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $375.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 154 | 319 | $53,635 | $20,237 |
| 2022 | 2 | 89 | 231 | $31,494 | $13,904 |
| 2021 | 3 | 132 | 251 | $43,321 | $19,604 |
| 2020 | 3 | 106 | 189 | $24,488 | $8,705 |
Total Patients
481
Total Services
990
Medicare Billing
$62,450
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 154 | 319 | $53,635 | $20,237 | 37.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 74 | 213 | $29,820 | $13,375 | 44.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 15 | 18 | $1,674 | $528.44 | 31.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 52 | 124 | $27,280 | $11,845 | 43.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 56 | 90 | $12,600 | $5,999 | 47.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 24 | 37 | $3,441 | $1,760 | 51.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 63 | 133 | $18,620 | $6,583 | 35.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 30 | 38 | $3,654 | $1,440 | 39.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 13 | 18 | $2,214 | $682.74 | 30.8% |
About Danielle Land, CRNP
Danielle Land, CRNP is a Family healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/02/2010. The National Provider Identifier (NPI) number assigned to this provider is 1730411786.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Danielle Land, CRNP has received a total of $44,958 in payments from pharmaceutical and medical device companies, with $3,797 received in 2024. These payments were reported across 69 transactions from 6 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($39,648).
As a Medicare-enrolled provider, Land has provided services to 481 Medicare beneficiaries, totaling 990 services with total Medicare billing of $62,450. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Family
- Location Philadelphia, PA
- Active Since 02/02/2010
- Last Updated 11/28/2011
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1730411786
Products in Payments
- IMBRUVICA (Drug) $20,423
- BRUKINSA (Drug) $14,978
- CALQUENCE (Drug) $8,470
- Veklury (Drug) $36.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Philadelphia
Bethany Thomas, Crnp, CRNP
Family — Payments: $99,046
Family $99,046
Anne Calvaresi, Crnp, CRNP
Family — Payments: $80,904
Family $80,904
Bethany Mooney, Crnp, CRNP
Family — Payments: $73,102
Family $73,102
Mrs. Susan Estrella-Eades, Crnp, CRNP
Family — Payments: $61,238
Family $61,238
Mrs. Eileen Mcdonnell, Crnp, CRNP
Family — Payments: $45,449
Family $45,449
Mrs. Michelle Vega-Olivo, Crnp, CRNP
Family — Payments: $41,856
Family $41,856